SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00222677

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.

To determine whether aspirin is more effective than placebo for the prevention of recurrent symptomatic venous thromboembolism when given for at least two years after the initial 6-12 month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism

NCT00222677 Venous Thromboembolism Deep Venous Thrombosis Pulmonary Embolism Atherosclerosis
MeSH:Pulmonary Embolism Thrombosis Atherosclerosis Thromboembolism Embolism Venous Thromboembolism Venous Thrombosis
HPO:Atherosclerosis Deep venous thrombosis Pulmonary embolism Thromboembolism Type IV atherosclerotic lesion Venous thrombosis

1 Interventions

Name: aspirin

Description: 100 mg daily
Type: Drug


Primary Outcomes

Measure: recurrence of VTE and/or VTE related death

Time: at least 24 months per patient

Secondary Outcomes

Measure: recurrent VTE+ death; cardiovascular events, bleeding events, critical ischemia of the lower limbs, mesenteric infarction, all cause mortality and newly diagnosed cancer

Time: at least 24 months per patient

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 G21210A

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A ---

Exclusion Criteria: - permanent risk factors for venous thromboembolism: patients known to have antiphospholipid antibodies or lupus anticoagulant (based on local laboratory criteria) or to have homozygous factor V Leiden or homozygous prothrombin G21210A or heterozygous factor V Leiden plus heterozygous prothrombin G21210A or antithrombin III deficiency; patients with active malignancy - temporary risk factors for venous thromboembolism - any recurrence of venous thromboembolism or bleeding episode during the established 6-month period of oral anticoagulant treatment - allergy or intolerance of aspirin - clear indication for aspirin or other anti-platelet therapy (e.g. --- G21210A --- --- G21210A ---



HPO Nodes


HPO:
Protein Mutations 0
SNP 0